Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials.
about
Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trialsManagement of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - SummaryCardiovascular effects of basal insulinsCardiovascular effects of antidiabetic agents: focus on blood pressure effects of incretin-based therapiesCellular and molecular mechanisms of metformin: an overviewDiagnosing and managing diabetes in HIV-infected patients: current conceptsClinical utility in the treatment of type 2 diabetes with the saxagliptin/metformin fixed combinationUpdate on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association.Metformin as a cellular protector; a synoptic view of modern evidencesCardiovascular risk factor management of myocardial infarction patients with and without diabetes in the Netherlands between 2002 and 2006: a cross-sectional analysis of baseline dataHarnessing publicly available genetic data to prioritize lipid modifying therapeutic targets for prevention of coronary heart disease based on dysglycemic risk.The relationship between hypomagnesemia, metformin therapy and cardiovascular disease complicating type 2 diabetes: the Fremantle Diabetes StudyPreadmission metformin use and mortality among intensive care patients with diabetes: a cohort study.MARCH2: comparative assessment of therapeutic effects of acarbose and metformin in newly diagnosed type 2 diabetes patientsFrailty Attenuates the Impact of Metformin on Reducing Mortality in Older Adults with Type 2 DiabetesCardiovascular safety profile of currently available diabetic drugs.Are concomitant treatments confounding factors in randomized controlled trials on intensive blood-glucose control in type 2 diabetes? a systematic review.Effect comparison of metformin with insulin treatment for gestational diabetes: a meta-analysis based on RCTs.Reduced vascular events in type 2 diabetes by biguanide relative to sulfonylurea: study in a Japanese Hospital Database.Five-year change of clinical and complications profile of diabetic patients under primary care: a population-based longitudinal study on 127,977 diabetic patients.Effect of metformin monotherapy on cardiovascular diseases and mortality: a retrospective cohort study on Chinese type 2 diabetes mellitus patients.Clinical Outcomes of Metformin Use in Populations With Chronic Kidney Disease, Congestive Heart Failure, or Chronic Liver Disease: A Systematic Review.Dissecting the Mechanisms Underlying Unusually Successful Human Health Span and Life Span.Insulin therapy and cancer in type 2 diabetes.Metabolic syndrome impairs reactivity and wall mechanics of cerebral resistance arteries in obese Zucker rats.Metformin versus placebo in combination with insulin analogues in patients with type 2 diabetes mellitus-the randomised, blinded Copenhagen Insulin and Metformin Therapy (CIMT) trial.Association of hypoglycemic treatment regimens with cardiovascular outcomes in overweight and obese subjects with type 2 diabetes: a substudy of the SCOUT trialRenoprotective Effects of Metformin are Independent of Organic Cation Transporters 1 &2 and AMP-activated Protein Kinase in the KidneyIs glucose control important for prevention of cardiovascular disease in diabetes?Cardiovascular safety of non-insulin pharmacotherapy for type 2 diabetes.Nutrients in Energy and One-Carbon Metabolism: Learning from Metformin Users.On the potential of acarbose to reduce cardiovascular disease.Optimal management of type 2 diabetes: the evidence.Overview of the guidelines and evidence for the pharmacologic management of type 2 diabetes mellitus.Saxagliptin plus metformin combination in patients with type 2 diabetes and renal impairment.Combining GLP-1 receptor agonists with insulin: therapeutic rationales and clinical findings.Individualized treatment of type 2 diabetes mellitus using noninsulin agents: clinical considerations for the primary care physician.Combine and conquer: advantages and disadvantages of fixed-dose combination therapy.Coronary heart disease in type 2 diabetes: mechanisms and comprehensive prevention strategies.
P2860
Q21144611-774C64AC-8641-45CC-9E42-94EC49EE7F25Q22241288-819F3768-165A-4CB1-A9A7-6BCEC2928A1CQ22241786-94D623BB-3DD0-49D6-8F1F-7B06144F61E2Q26800249-D4B2B4C5-CB0E-4DBA-97BA-8045AEFE9BD5Q26866958-FF0BB06D-ED33-4240-A115-EA425F1CE0E7Q27013561-E1778A05-F22B-423D-8DC7-E136D57C27BFQ27014697-08F0E1E1-C2EA-4DB8-9B95-FD48215DFFFDQ27026211-0C90B2C2-4D13-4A1B-8637-2FB63BA410B6Q27687851-D58A885A-4885-49E9-AA29-270B5DA0E34EQ28817196-4F2DDD6D-F6AD-411F-BA60-F1825BD07216Q30530802-BCB8DEB7-7F65-46EE-A415-18F0863D2AC6Q31053398-11A6334C-6F14-422A-9814-02F77D81B486Q31138001-B05FBD0E-48C0-4812-9877-38F2894C0CBDQ33754815-5C43F7CD-3848-47DB-A5EB-0E2F9B385AC7Q34078741-E9AD91D7-F734-44E7-B067-B360E177A4DBQ34684420-C4818BEE-B6F3-4AD4-B8AE-C2AE2FCC77C4Q34971736-27B7F194-0FA3-4384-97B3-DDF6CB24AF31Q35042647-ADBD63FF-C49E-443A-A040-36B0E571546BQ35535310-C5DD2C52-2C56-4E5A-99C1-21226E17C95AQ35780117-383E1ACD-4B7E-441A-A3BC-A068F939ADCBQ36071201-1D623844-E10A-4463-924D-E5ED6B745532Q36144000-BFB58DE5-2BDC-4B2B-8CFA-68CC0084B701Q36240156-8904CF17-10D1-4CD0-B904-6C14384E9C67Q36406255-48F4911E-609A-425C-B268-1FFF34FD8562Q36417868-95675619-5994-472E-8863-A4DA99202E9AQ36422434-4AC60369-DEB2-4638-835F-E12A4CCD822EQ36633074-C394A543-65AE-438A-8F55-A9C7C787C26CQ37277912-C0D4C6C6-2C22-42A4-A73B-BA0944B761C9Q37366972-E406DD18-8FCD-48E2-B33F-90F11A17794DQ37577137-CA05826D-86EE-4AC2-B12B-C31782489FDEQ37620904-40600A7B-2693-4959-8AF1-836C37E444D5Q37673171-706D9243-30AA-4B77-9713-385928B437C5Q37717838-FAE96F5E-51F8-4C79-BA1A-809359E6AC20Q37961236-4790153F-3DF2-4BD0-BD66-28BE74F74635Q37961846-9B7CCD7D-BACC-4584-AEF3-EC8C8B937956Q37982112-9578D5E4-7CCB-4EE8-AC35-60710562E9C2Q38014516-4DBA653F-F6FF-4637-B2A3-395DAA6F78EAQ38036773-A127EA59-418F-4F1D-BF80-FBC6CD16A9BFQ38046641-2071A5DD-23F6-47C6-9D16-872CCFDCD779Q38048842-AB7D2E09-6C3F-44F7-A60B-4A6794DD4031
P2860
Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մարտին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Effect of metformin on cardiov ...... of randomized clinical trials.
@ast
Effect of metformin on cardiov ...... of randomized clinical trials.
@en
type
label
Effect of metformin on cardiov ...... of randomized clinical trials.
@ast
Effect of metformin on cardiov ...... of randomized clinical trials.
@en
prefLabel
Effect of metformin on cardiov ...... of randomized clinical trials.
@ast
Effect of metformin on cardiov ...... of randomized clinical trials.
@en
P2093
P2860
P921
P1476
Effect of metformin on cardiov ...... of randomized clinical trials.
@en
P2093
E Mannucci
N Marchionni
P2860
P304
P356
10.1111/J.1463-1326.2010.01349.X
P577
2011-03-01T00:00:00Z